Celastrol Enhanced Doxorubicin-Mediated Apoptosis in Saos-2 Osteosarcoma Cells

Fatemeh Pilevar1, Dariush Shanehbandi2, Amir Valizadeh3

  • 1Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran, tbzmed.ac.ir.

Abstract

Insights

Celastrol enhances doxorubicin

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Osteosarcoma is a highly lethal human malignancy.
  • Natural compounds from plant foods show anticancer properties like antiproliferative and proapoptotic effects.

Purpose of the Study:

  • Investigate celastrol's effects on doxorubicin-induced apoptosis in osteosarcoma (Saos-2) cells.
  • Evaluate combined treatment of doxorubicin and celastrol.

Main Methods:

  • MTT assay for cytotoxicity.
  • Flow cytometry for apoptosis quantification.
  • Western blot and qRT-PCR for apoptosis mediator expression.
  • ELISA for apoptosis measurement.

Main Results:

  • Celastrol amplified doxorubicin's cytotoxic effects in Saos-2 cells.
  • Combined treatment significantly boosted apoptosis.
  • Modulation of key apoptosis mediators (Bax, Bcl-2, caspase-3, cytochrome c, p53) observed.

Conclusions:

  • Doxorubicin and celastrol combination potentiates doxorubicin-mediated apoptosis in osteosarcoma.
  • This combination therapy shows promise for osteosarcoma treatment.

Related Concept Videos